


| 28 | Octol | ber 2 | 019 |
|--------------|----------|-------|------|
| Equity | Res | ear | ch |
| research@arm | securiti | es.co | m.ng |
| | +234 1 | 270 | 1652 |

| Rating | NEUTRAL |
|-----------------------|--------------------|
| Price | N 46.05 |
| FVE | N 76.58 |
| 52-week range | N 46-88 |
| Market Cap. (₦'mn) | 386,257.3 |
| l-month Avg. Vol | 4,961,179 |
| Curr. PE | 21.55x |

NB:NL - Share Price Trend



Damilola Olupona damilola.olupona@arm.com.ng

Nigeria Breweries Plc. (NB.NL)

Initial View

NB growing sales at a higher cost

- Nigerian Breweries Plc released Q3 19 result last week, recording loss after tax of N1 billion (Q3 18 loss after tax of N3.6 billion). The poor earnings performance mirrors higher excise duty, elevated operating and finance expenses. The losses over Q3 19, trimmed 6M 19 EPS (N1.63) to N1.53 over the first nine months of the year. On its 9M 19 earnings, the company declared an interim dividend of N0.50. Our full year dividend forecast of N2.58 translates to dividend yield of 6% at current pricing.
- NB growing sales, at a higher cost. Akin to trend over the last three quarters, NB reported a 3% YoY growth in gross revenue to N73.2 billion, with management linking this to low-single digit growth in beer volumes and double-digit increase in the premium portfolio driven by Heineken. However, on the heels of higher excise duty (+31% YoY to N7.7 billion), net revenue was largely flat at N65.4 billion from last year. On the positive, despite higher barley prices (+18% YoY), the company reported lower cost of sales (-12.4% YoY to N40.9 billion), which mirrors better economies of sales from higher beer volumes over the period. As a result, gross margin expanded to 37.4% in Q3 from 28.5% in Q3 18.
- While the company has successfully grown beer volumes despite intense industry competition, it has been doing so at a cost. For context over the last two quarters the company has reported OPEX to sales ratio higher than its historical average (5-year average: 26.8%). In fact, Q3 19 OPEX to sales of 36.9% is the highest since 2012. While this has resulted in positive sales growth over the last few quarters, we question the sustainability of this strategy going forward, as operating margins are nearing its trough (EBIT margin: 1.1% in Q3 19). Further exacerbating the weak operating profit, finance expense more than doubled, increasing to N2.9 billion (Q3 18: N1.2 billion) following increase in short term borrowings (+91% YoY to N32.8 billion).
- Despite growth in sales which have been the main pressure point for the company in time past, we question the sustainability of its higher operating expense and envisage either of the following in the coming quarters 1.) cut back its operating expenses 2.) increase in prices to compensate for higher excise duties or 3.) a combination of 1 and 2. Based on our last communicated FVE of N75.82, we have a BUY recommendation on the company. NB trades at a P/E of 21.5x relative to 12.22x and 18.97x for Guinness and Bloomberg MENA peers.

| Summary of Results | | | | | | |
|--------------------------------|---------|-----------|---------|-----------|-----------|------------|
| Income statement – (N'million) | Q3 19 | Q3 18 YoY | growth | QoQ Growt | h 9M 19 | YoY growth |
| YE – Dec | | | | | | |
| Revenue | 65,488 | 65,406 | 0.1% | -24.7% | 235,679 | -1.0% |
| Cost of sales | -40,966 | -46,772 | -12.4% | -18.6% | (139,506) | -2.7% |
| Gross profit | 24,522 | 18,634 | 31.6% | -33.0% | 96,173 | 1.5% |
| Operating expenses | -24,165 | -24,323 | -0.6% | -8.7% | (71,776) | 6.1% |
| Operating profit | 710 | -3,875 | -118.3% | -93.2% | 25,173 | 17.8% |
| Net interest expense | -2,897 | -1,200 | 141.5% | 18.1% | (7,951) | 51.0% |
| РВТ | -2,188 | -5,074 | -56.9% | -127.5% | 17,222 | -23.4% |
| | | | | | | |
| РАТ | -1,043 | -3,645 | -71.4% | -119.7% | 12,275 | -17.0% |

| Key Ratios | Q3 19 | Q3 18 | Change(pps) | 9M 19 | 9M 18 | Change(pps) |
|---------------------|-------|-------|-------------|-------|-------|-------------|
| Gross margins | 37.4% | 28.5% | 9.0% | 40.8% | 39.8% | 1.0% |
| EBIT margins | 1.1% | -5.9% | 7.0% | 10.7% | 10.9% | -0.2% |
| PBT margins | -3.3% | -7.8% | 4.4% | 7.3% | 8.8% | -1.5% |
| PAT margins | -1.6% | -5.6% | 4.0% | 5.2% | 5.8% | -0.6% |
| Effective tax rates | 52.3% | 28.2% | 24.2% | 28.7% | 34.2% | -5.5% |

ARM ratings and recommendations

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

| ТОР 20 | | NON-TOP 20 | |
|-------------|-----------|------------|-----------|
| Rating | Deviation | Rating | Deviation |
| STRONG BUY | >20% | BUY | >20% |
| OVERWEIGHT | 10% 20 % | NEUTRAL | 5% - 20 % |
| NEUTRAL | 0% 10 % | SELL | <5% |
| UNDERWEIGHT | -5% 0% | | |
| SELL | <-5% | | |

| RECOMMENDATION KEY | | | | |
|--------------------|---|--|--|--|
| Rating | Recommendation | | | |
| BUY | Accumulate security to a substantial extent constrained only by portfolio diversification considerations | | | |
| OVERWEIGHT | Accumulate security to an extent moderated by cognizance of its benchmark weight | | | |
| NEUTRAL | Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—sult reasonable portfolio constraints | | | |
| UNDERWEIGHT | Minimize exposure to security taking cognizance of its index weighting | | | |
| SELL | Sell-off security completely from portfolio | | | |

Copyright © 2019 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorised use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.